Treace Medical Concepts (TMCI) Q2 2026: 40% Surgeon Adoption of New Bunion Systems Drives Case Volume Growth
Treace Medical Concepts’ second quarter saw a clear inflection in case volume growth and product adoption, with 40% of its surgeon base now using at least one of its three new bunion systems. Despite a year-over-year revenue decline, operational leverage and cash discipline improved, and management raised full-year guidance on the back of sustained market share gains and upcoming product launches. Momentum in portfolio expansion and cross-sell is setting up a stronger exit rate into 2027, with competitive differentiation visible in both technology and surgeon engagement.
Summary
- Surgeon Penetration Accelerates: 40% of Lapoplasty users have adopted new bunion systems, expanding wallet share.
- Operational Efficiency Gains: Lower cash burn and OpEx signal improved cost discipline and leverage.
- Portfolio Expansion in Play: Midfoot and hindfoot launches open a $300M TAM, supporting future growth runway.
Business Overview
Treace Medical Concepts develops and commercializes specialized surgical solutions for foot and ankle conditions, with a core focus on bunion correction. The company’s revenue model centers on procedure-based product sales to orthopedic surgeons, with its Lapoplasty system as a flagship offering. Major segments include bunion correction (Lapoplasty, Adductoplasty, Nanoplasty, Percuplasty, Speed MTP) and adjacent foot and ankle procedures (SuperBite compression screw, HyperPlate XM, Great Release XM, Cartoblaster), primarily distributed via a direct sales force that accounts for roughly 80% of total revenue.
Performance Analysis
Revenue declined 4% year-over-year in Q2, but the company delivered sequential improvement in case volume growth, now reaching high single digits versus prior quarters’ mid single digits. This acceleration is directly attributed to increased adoption of the three new bunion systems, which have now penetrated 40% of the 3,300-surgeon customer base, up from 35% in Q1. The introduction of the SuperBite compression screw contributed incremental volume, supporting a broader procedural reach.
Operating expenses decreased by 8% year-over-year, reflecting ongoing cost discipline and the annualization of restructuring initiatives begun in 2025. The net loss narrowed, and cash usage was reduced by 57%, demonstrating improved operational leverage even as the company continues to invest in R&D and commercial expansion. Management raised full-year revenue guidance, citing confidence in continued volume uptick and the lapping of adverse ASP mix effects from last year’s product launches.
- Case Volume Growth Inflection: High single-digit case growth signals successful commercial execution and market share gains.
- Cost Structure Improvement: Lower OpEx and cash burn provide a foundation for margin expansion as revenue rebounds.
- Seasonality and Launch Cadence: Q4 is expected to be the strongest quarter, with new product launches timed to maximize impact.
With new platforms entering commercialization and strong pull-through across the surgeon base, TMCI’s exit velocity for 2026 is positioned to support a return to positive revenue growth in the fourth quarter.
Executive Commentary
"We are pleased with our results in the second quarter with our revenue growth rate improving sequentially and our focus on profitability generating stronger adjusted EBITDA and reduced cash usage over prior year... These results were driven by continued year-over-year case volume growth which accelerated to high single digits in the quarter and market share gains driven by increasing surge in adoption of our comprehensive bunion portfolio and early impact of our expanding line of new technologies now allowing us to tap into a broader range of procedures throughout the foot and ankle."
John Treace, Chief Executive Officer
"We did better in adjusted EBITDA in Q2 this year versus last year on a lower revenue base. And so we believe that there is improved leverage in the system... We continue to look for efficiencies throughout the organization. We believe we can improve some of the leverage, some of the benefits to the bottom line. And we want to do that in a way that's not going to hurt our investments into top line growth, meaning we continue to invest in our great R&D program."
Mark Hair, Chief Financial Officer
Strategic Positioning
1. Bunion Portfolio Penetration
TMCI’s three new bunion systems—Nanoplasty, Percuplasty, and Speed MTP—are designed to address the 75% of bunion procedures not historically served by Lapoplasty, unlocking significant incremental volume. With 40% of Lapoplasty users now adopting these new systems, the cross-sell strategy is driving both utilization and surgeon stickiness.
2. Core Franchise Reinforcement
Lapoplasty remains the anchor for TMCI’s leadership in the Lapidus fusion segment, representing about 30% of annual U.S. bunion procedures. The upcoming Lapoplasty Lightning and Intelliguide PSI launches are aimed at workflow simplification and improved accuracy, further entrenching TMCI’s competitive moat among high-volume surgeons.
3. Adjacent Procedure Expansion
Expansion into midfoot and hindfoot fusion procedures through SuperBite, HyperPlate XM, and Great Release XM opens a $300 million U.S. addressable market, according to management. These technologies enable the sales force to participate in a broader array of surgeries, boosting overall wallet share and providing natural cross-sell opportunities with existing customers.
4. Commercial Channel Leverage
Direct sales coverage remains a key differentiator, with roughly 80% of revenue coming through this channel. TMCI’s best-in-class medical education and surgeon onboarding programs are cited as critical drivers of adoption and loyalty, especially as new technologies come to market.
5. Innovation Pipeline and Competitive Barriers
Management emphasizes a robust innovation cadence, with multiple launches slated for late 2026 and beyond. The combination of rapid iteration, surgeon education, and specialized sales support has so far limited competitive encroachment, despite the presence of larger and smaller rivals in the bunion space.
Key Considerations
TMCI’s strategic trajectory is defined by expanding procedural reach, operational discipline, and surgeon engagement, all while navigating a competitive orthopedic landscape. Success will hinge on the company’s ability to sustain adoption momentum, execute on its product pipeline, and maintain cost control as it scales.
Key Considerations:
- Cross-Sell Uptake: The 40% adoption of new bunion systems by Lapoplasty surgeons validates the multi-platform strategy and supports future wallet share expansion.
- ASP and Mix Dynamics: Lower ASPs from new MIS (minimally invasive surgery) products are being offset by higher-complexity, multi-product cases in midfoot and hindfoot, with average procedure value expected to stabilize as the portfolio matures.
- Seasonality: Q4 remains the strongest period for bunion procedures, and product launches are strategically timed to capture this demand spike.
- Cash and Profitability Discipline: Meaningful OpEx reductions and lower cash burn increase the likelihood of positive adjusted EBITDA in 2027.
Risks
Competitive response remains a core risk, as larger orthopedic players could accelerate innovation or pricing pressure in the bunion and adjacent markets. ASP headwinds from lower-priced MIS products will persist through Q3, and any slowdown in elective procedures or shifts in insurance coverage could impact case volumes. Execution risk around new product launches and surgeon training is also material, given the centrality of adoption to the growth thesis.
Forward Outlook
For Q3 2026, TMCI expects:
- Sequential revenue growth driven by continued volume increases and new product contributions
- Continued moderation of ASP headwinds as mix effects from 2025 launches annualize
For full-year 2026, management raised guidance:
- Revenue of $204 million to $212 million, a narrowing of the prior range and an increase at the low end
- Adjusted EBITDA loss of $3 million to $5 million, improved from previous guidance
Management highlighted several factors that will shape the back half:
- New product launches (Lapoplasty Lightning, Cartoblaster, full SuperBite rollout) are expected to drive incremental case volume
- Q4 is anticipated to be the seasonally strongest quarter, with a step-up in both revenue and case volumes
Takeaways
TMCI’s Q2 2026 results highlight successful execution on portfolio expansion and operational leverage, positioning the company for a return to growth and improved profitability as it exits the year.
- Surgeon Adoption as Growth Lever: Rapid uptake of new bunion systems is driving case volume and validating TMCI’s multi-platform approach.
- Cost Structure Realignment: Lower OpEx and cash usage establish a credible path toward positive adjusted EBITDA in 2027.
- Portfolio Broadening as Risk Mitigation: Expansion into adjacent foot and ankle procedures diversifies revenue streams and buffers against single-product concentration risk.
Conclusion
TMCI’s second quarter underscores a turning point in product adoption and operational discipline, with management executing against a clearly defined strategy. The combination of accelerating case growth, expanding procedural reach, and disciplined cost management supports a constructive outlook as the company enters its seasonally strongest period and prepares for further innovation-driven growth.
Industry Read-Through
TMCI’s experience this quarter provides a window into broader trends in orthopedic medtech: Portfolio breadth, surgeon engagement, and direct commercial execution are increasingly critical as ASP pressures and competitive intensity persist. The success of cross-sell and adjacencies highlights the importance of leveraging anchor products to expand share of wallet. For other orthopedic and specialty device players, timing product launches to seasonality and investing in education and support infrastructure are emerging as key differentiators. The ability to combine innovation with cost discipline will be central to sustaining growth and profitability in a crowded market.